Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

10.1186/bcr3231

Saved in:

Bibliographic Details
Main Authors:	Byrski, T, Dent, R, Blecharz, P, Foszczynska-Kloda, M, Gronwald, J, Huzarski, T, Cybulski, C, Marczyk, E, Chrzan, R, Eisen, A, Lubinski, J, Narod, S.A
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	aromatase inhibitor BRCA1 protein cisplatin cyclophosphamide dexamethasone docetaxel doxorubicin epidermal growth factor receptor 2 estrogen receptor fluorouracil ondansetron pabi dexamethason progesterone receptor unclassified drug antineoplastic agent adult aged anemia article breast cancer cancer chemotherapy cancer survival clinical article drug withdrawal female gene mutation heterozygote human metastasis multiple cycle treatment nausea neutropenia open study overall survival phase 2 clinical trial treatment outcome Breast Neoplasms clinical trial computer assisted tomography genetics metabolism middle aged mortality multicenter study mutation pathology tumor suppressor gene Adult Aged Antineoplastic Agents Cisplatin Female Genes, BRCA1 Heterozygote Humans Middle Aged Mutation Neoplasm Metastasis Receptors, Estrogen Receptors, Progesterone Tomography, X-Ray Computed Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183230
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items